This line of research matters for how we think about treatment access and stigma. If medications prescribed for metabolic health also reduce the risk of addiction or severe outcomes, clinicians and patients face new decisions about who might benefit and how to combine therapies safely. The biological insights behind these findings could open routes to interventions that support long-term recovery, especially for groups that have limited treatment options.
Curious about the evidence and what it implies for people, clinicians and policy? The study raises questions about mechanism, who benefits most, and how this could change clinical practice and public health planning. Follow the link to read how these unexpected connections between metabolism and addiction might reshape our approach to human potential, resilience and inclusion in treatment.
A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction itself. Researchers found that people taking these medications were less likely to develop substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other drugs, while those already struggling with addiction experienced fewer overdoses, hospitalizations, emergency visits, and drug-related deaths.
